Israel's new drug EXO-CD24: 90% of patients with COVID-19 discharged from hospital within 5 days! Fight the cytokine storm!
The new drug is a new drug developed by a team at Sourasky Medical Center in Tel Aviv. "The main goal of this research is to verify whether the drug is safe," said Professor Nadir Arber. "Until today, we have not found any significant side effects in the two groups of patients."

Picture from Al-Ittihad screen
The trial was conducted in Athens because (at the time) there were not enough relevant patients in Israel. The lead researcher is Professor Sotiris Tsiodras, a Greek coronavirus expert. Arber and his team, including Dr. Shiran Shapira, developed the drug based on a molecule called CD24 that the professor has studied for 25 years, which is naturally present in the body.
Clinically, the main reason for the deterioration of the patient's condition is the excessive activation of the immune system, also known as cytokine storm. The drug is aimed at cytokine storm. CD24 is a protein fixed on the cell membrane. It has many functions, including the mechanism of regulating cytokine storms.
Arber emphasized that EXO-CD24 will not affect the entire immune system, but only for this specific mechanism to help find its correct balance again. "We are using the body's endogenous mechanisms to balance the cytokine storm part."
Arber pointed out that another breakthrough of this treatment is its delivery. "We are using exosomes, which are very small vesicles that originate from the cell membrane and are responsible for the exchange of information between them," he said. "By trying to transport them exactly where they are needed, we have avoided many side effects."
Looking for chemical products? Let suppliers reach out to you!
New Drug Approvals
2026-07-13
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Roche Keeps German Diagnostics Investment
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
India Raises Cancer Drug Price Caps by 50%
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
60 Percent Workforce Held by Top 10 Firms! China’s TCM Industry Faces Fierce Reshuffle as Private Leaders Expand Fast
-
₹27,548 Crore Pharma Giant Cipla Enters Weight Management Battle as Obesity Demand Surges
Recommend Reading
-
Trump Warns of 200 Percent Tariffs on Pharma Companies by August 1 India Trade Deal Among Top Priorities
-
Emcure Seals Exclusive Deal for Sanofi’s Oral Diabetes Brands Millions of Indian Patients to Benefit
-
AstraZeneca Rare Disease Drug Misses Phase 3 Target Hope Shifts to Subgroup Data
-
Over 22,000 New Cases in India AstraZeneca Gets CDSCO Green Light for Muscle-Invasive Bladder Cancer Drug
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
This week, the price trend of China's 180CST fuel oil is downward
-
Premium Global Chemical Sourcing Requests (19 - 22 Mar, 2026)
-
Cost support weakens, polyester staple fiber prices continue to decline
-
ECHEMI and CPHI China Jointly Host Pharmaceutical Business Match-making Event
-
This Week’s Petroleum Coke Market in Local Refineries Shows Weak and Consolidating Trends